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Abstract
The genome-wide association study (GWAS) approach has discovered hundreds of genetic variants associated with diseases
and quantitative traits. However, despite clinical overlap and statistical correlation between many phenotypes, GWAS are
generally performed one-phenotype-at-a-time. Here we compare the performance of modelling multiple phenotypes jointly
with that of the standard univariate approach. We introduce a new method and software, MultiPhen, that models multiple
phenotypes simultaneously in a fast and interpretable way. By performing ordinal regression, MultiPhen tests the linear
combination of phenotypes most associated with the genotypes at each SNP, and thus potentially captures effects hidden
to single phenotype GWAS. We demonstrate via simulation that this approach provides a dramatic increase in power in
many scenarios. There is a boost in power for variants that affect multiple phenotypes and for those that affect only one
phenotype. While other multivariate methods have similar power gains, we describe several benefits of MultiPhen over
these. In particular, we demonstrate that other multivariate methods that assume the genotypes are normally distributed,
such as canonical correlation analysis (CCA) and MANOVA, can have highly inflated type-1 error rates when testing case-
control or non-normal continuous phenotypes, while MultiPhen produces no such inflation. To test the performance of
MultiPhen on real data we applied it to lipid traits in the Northern Finland Birth Cohort 1966 (NFBC1966). In these data
MultiPhen discovers 21% more independent SNPs with known associations than the standard univariate GWAS approach,
while applying MultiPhen in addition to the standard approach provides 37% increased discovery. The most associated
linear combinations of the lipids estimated by MultiPhen at the leading SNPs accurately reflect the Friedewald Formula,
suggesting that MultiPhen could be used to refine the definition of existing phenotypes or uncover novel heritable
phenotypes.
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Introduction
Genome-wide association studies aim to identify associations
between genotype and phenotype. While genotypes are well-
defined biological entities, phenotypes are defined more subjec-
tively and can relate to numerous biological processes. There has
been much effort to characterise well-defined phenotypes that may
correspond more to specific biological function for use in genome-
wide association studies, but the definition of some phenotypes
remains somewhat ad-hoc. Type 2 diabetes, the subject of the first
major genome-wide association study [1], is diagnosed using a
debated blood glucose threshold [2], the Metabolic Syndrome is
commonly based on observing three of five criteria [3], while
neuropsychiatric disorders rely on a complex range of overlapping
clinical characteristics for diagnosis.
While most quantitative traits are less ambiguously defined,
many are defined as mathematical functions of several measure-
ments in an attempt to better capture the underlying biology than
individual quantities. There have been many more genetic
determinants of Body-mass-index (BMI), defined as the ratio of
weight to height squared, discovered than those of weight [4], and
the significance of rs8050136 in FTO was reported to be 11 orders
of magnitude more significant for BMI than weight [5]. Illig et al.
[6] investigated genetic association with metabolites and all
metabolite ratios, using metabolite ratios as proxies for enzymatic
reaction rates.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e34861A primary aim of this study is to fully assess the performance of
a multivariate approach to genome-wide association studies in
comparison to that of the usual single-phenotype strategy. Rather
than exploiting an available multivariate method, we introduce a
new fast and interpretable approach, which addresses some of the
limitations of previously suggested methods. In particular, we
propose that linear combinations (equivalent to ratios on pre log-
transformed phenotypes) of directly measured phenotypes may
often capture unmeasured aspects of complex biological networks,
such as reaction rates, protein mediators or other uncharacterised
or clinically-inferred phenotypes. Modelling the association
between linear combinations of phenotypes and the genotypes at
each SNP may uncover genetic association hidden to both single
phenotype GWAS and those based on a priori defining a phenotype
as a fixed function of traits. Such an approach circumvents the
problems of phenotype definition by enabling association of
genotype with flexible linear combinations of robust measure-
ments, and could potentially be exploited by biologists and
clinicians to define phenotypes that better reflect underlying
biological processes.
We introduce a new method, MultiPhen, that rapidly performs
GWAS on multiple phenotypes by identifying the linear combi-
nation of the phenotypes most associated with genotype at each
SNP. This is achieved by reversing the regression, such that
genotype is regressed on phenotype, rather than phenotype-on-
genotype as in the standard GWAS approach. By applying ordinal
regression (proportional odds logistic regression), which models the
genotype data as ordinal, multiple phenotypes can then be jointly
modelled as predictors of the SNP genotypes to test for multi-
phenotype associations (see Methods). This model makes no
assumption on the phenotype distribution and so can accommo-
date both binary and continuous measurements. Our test for
association is a likelihood ratio test for model fit, which provides a
P value for evidence of association between the SNP and the
phenotypes. The usual genome-wide significance level is applied.
While several approaches to multivariate analysis of GWAS have
been introduced in recent years, the univariate approach is still
routinely favoured [7–9]. We believe that this is partly due to a
lack of thorough comparison between a multivariate and the
univariate approach, which we seek to address here, and also
potentially due to limitations in the multivariate methods, such as:
not allowing joint analysis of continuous and binary phenotypes
[10–11], having inflated type 1 error [11], reducing the effective
sample size by requiring cross-validation [12], and not explicitly
modelling the correlation structure between traits [13–14].
MultiPhen does not suffer from these problems, but the benefit
of using MultiPhen over ‘canonical correlation analysis’ (CCA)
[15], when testing one-SNP-at-a-time, is less clear due to their
similarity. MultiPhen and CCA (as implemented by Ferreira and
Purcell [15]) both test the linear combination of the phenotypes
most associated with the genotypes of a SNP against a null
hypothesis of no association, but while CCA treats the genotypes
as normally distributed MultiPhen appropriately models the
genotypes as ordinal. Based on this, we specifically investigate
whether MultiPhen offers better performance than CCA (which is
equivalent to ‘reversed’ linear regression, with SNP as outcome,
and MANOVA).
We show via simulation that MultiPhen has markedly higher
power than the standard single-phenotype approach to detect
SNP-phenotype associations in many scenarios, even for identify-
ing variants that affect only one of the phenotypes, as a result of
jointly modelling the phenotypes. In addition, there are several
convenient aspects of adopting our approach. As the phenotypes
are treated as predictors rather than outcomes, there is no need to
ensure their normality via transformation. Our MultiPhen
software (available as a CRAN package for R) appropriately
handles imputed SNP data and CNVs, can optionally perform a
score test, and can perform univariate linear (standard) and
ordinal (reversed) regressions for comparison with multivariate
results (see Methods). A further advantage of our approach is its
computational speed; applying MultiPhen to 10 traits is around
1.3 times faster than the corresponding set of standard single-
phenotype analyses. With a natural test for combining results
across studies as the (weighted) sum of the likelihood ratios (or z
scores) from each study, MultiPhen can be easily applied to
perform meta-analysis of measured or imputed SNP data across a
large number of phenotypes and studies. The similarity of the
approach to that of the usual linear and logistic regressions
performed in GWAS, and the presentation of P values for
association in the usual way, make the approach highly
interpretable and a natural extension of current methods for
GWAS.
Results
Type 1 Error Rate Assessed by Simulation
We first assess whether MultiPhen, CCA [15] and the standard
univariate approach have appropriate type 1 error by simulating
sets of 100000 SNPs under the null hypothesis of no association,
for 2 continuous phenotypes with correlations between the
phenotypes of up to r=0.9 (where r is Pearson’s correlation
coefficient). Here and subsequently, the univariate P value is
calculated as the minimum univariate P value across the tested
phenotypes corrected for the effective number of tests by applying
a ‘‘Nyholt-S ˇida ´k correction’’ [16] (see Methods). For normally
distributed phenotypes tested at common and rare SNPs
(MAF=30% and 0.5%, N=5000), MultiPhen, CCA and the
Nyholt-S ˇida ´k corrected univariate approach generate uniform P
values, and thus successfully control the false-positive rate (Figures
S1 and S2). This is also the case when one of the phenotypes is
simulated to have a distribution with outliers, such that the error
term is simulated from a t-distribution with 3 degrees of freedom
rather than a Normal distribution, when tested at common SNPs
(Figure S3). However, there is substantial inflation of the statistics
for both CCA and the univariate approach for low frequency
variants when the phenotype distribution includes outliers (Figure
S4). We also show that there is inflated type 1 error for CCA and
the univariate approach in this scenario for common SNPs, with
MAF=5%, when the sample size is small, N=200 (Figure S5).
Finally, we investigate the type 1 error rates of the three methods
when applied to binary phenotypes, and find that while all three
methods have appropriate type 1 error rates when tested at SNPs
with MAF=30% (Figure S6) there is inflation of the statistics for
CCA and the univariate approach when MAF=0.5% and
N=5000 and when MAF=5% and N=200 (Figures S7 and
S8). Tables S1, S2 and S3 provide the number of results with P
values smaller than several thresholds in each of these scenarios,
while Table 1 shows the number of results with P,1e
–5, for which
the expectation under the null is one, for each of the methods
when the phenotypes have a correlation coefficient of 0.5. These
results suggest that the assumption of normality of the genotypes
made by the CCA method can critically compromise the approach
in certain scenarios.
We note that when CCA is applied one-SNP-at-a-time, as in
Ferreira and Purcell [15], its test statistic is equivalent to an F-test
in a linear regression model with SNP genotypes as outcome and
to a MANOVA test, and therefore these approaches have the
Joint Model of Multiple Phenotypes in GWAS
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here.
Statistical Power Assessed by Simulation
To formally compare the statistical power of MultiPhen, CCA
and separately performed single phenotype analyses, we conduct-
ed a simulation study. We first investigate the potential power
gains of using a multivariate approach over the standard
univariate approach, then subsequently assess differences in power
between the multivariate methods. We simulated replicates of a
causal variant under several scenarios of its effect on two
(simulated) continuous phenotypes. We simulated 10000 replicates
of a causal SNP in a sample of 5000 individuals, where the risk
allele explains 0.5% of the variance in the first phenotype and, in
turn, 0.5%, 0.1% and 0% of the variance in the second phenotype.
We simulate the variant as having different effects on the two
‘measured’ phenotypes in order to model association of the SNP
with different linear combinations of the phenotypes. These
scenarios were simulated across the range of between-phenotype
correlations, from r=–0.9 to r=0.9 in increments of 0.1. We first
tested for SNP-phenotype associations by performing single
phenotype analyses, calculating the Nyholt-S ˇida ´k corrected
minimum P value from the two analyses for each SNP. Next we
applied MultiPhen to the same data and performed the likelihood
ratio test for overall model fit, obtaining a P value for association
with the phenotypes (see Methods for details of simulation study).
Figure 1 compares the power of the methods to identify
associations at the genome-wide significance level (P=5x10
–8)
under these scenarios. MultiPhen outperforms the single-pheno-
type approach in detecting direct effects for the majority of the
scenarios considered, and in many cases the boost in power is
dramatic. MultiPhen performs particularly well when the genetic
effects are not in the same direction as the correlation between the
two phenotypes. For instance, when a variant only affects one of
two highly correlated phenotypes, or a variant affects negatively
correlated phenotypes in the same direction or positively
correlated phenotypes in opposite directions (Figure S9). Exem-
plars of the last scenario are HDL variants, which may have
opposite effects on total cholesterol and LDL (see Figure 2). If the
genetic effects are consistent with the correlation between the two
phenotypes, then the single phenotype approach is slightly more
powerful, for example, if the variant has the same effect on two
highly correlated phenotypes, or only affects one of two
uncorrelated phenotypes.
We note that, from a theoretical perspective, the power of
MultiPhen using two phenotypes P1 and P2, is worst when the
association of P2 with genotype G is entirely explained by P1, that
is when P2 is conditionally independent of G given P1. We show
that this corresponds to the situation in which the ratio of the effect
sizes b2/b1=r (the correlation between the phenotypes), assuming
P1 and P2 both have a variance of 1 (see Methods). This could
occur if P2 is immediately downstream of P1 in a biological
pathway with no other P2-regulators associated with G. Con-
versely MultiPhen is expected to perform better when b2/b1 is not
equal to r, that is, when the genetic effects are not in the same
direction as the correlation. While we would expect effects of
variants that explain a large proportion of phenotypic variation to
be consistent with the correlation of the phenotypes, this may not
be the case for variants that explain only a small portion of
phenotypic variation, such as those discovered in GWAS. Given
the complexity of biological pathways, we suggest that in many
cases genetic effects will not have the same correlation structure as
the phenotypes themselves. In these circumstances, we would
expect that MultiPhen has an advantage over traditional single-
phenotype approaches.
To investigate the generalisability of the results of Figure 1 to
more than two phenotypes we extended the simulations to three,
five and ten phenotypes. In general MultiPhen performs even
better with additional phenotypes in the scenarios where it
outperforms the univariate approach, but even worse with more
phenotypes when it has low power compared to the univariate
approach (Figure S10). With a large number of correlated
phenotypes the most likely scenario of effects may be that where
the variant has different sized effects on several phenotypes, which
is best captured by the middle panel of Figure S10 in which
MultiPhen has improved overall performance with increasing
phenotypes.
Next, we investigate the performance of MultiPhen when
applied to case-control data. Figures S11 and S12 show that
MultiPhen outperforms the univariate approach in the majority of
the model space when applied to two case-control phenotypes, and
when applied to a case-control phenotype and quantitative
phenotype together.
Finally, we compared the statistical power of CCA (equivalently
‘reversed’ linear regression and MANOVA) and MultiPhen. Since
the type 1 error rate of CCA is inflated for non-normal phenotypes
in the scenarios we considered (see above), it is difficult to make a
meaningful assessment of power in these scenarios. Therefore we
restricted our analysis to normally distributed phenotypes. Figure
S13 shows that while the power of CCA is in general marginally
higher than MultiPhen, the difference is negligible. As a result, in
the empirical example that follows we only compare MultiPhen
with the standard univariate approach.
Table 1. Behaviour of the different methods under the null.
Phenotypes MultiPhen CCA Univariate
30% 0.5% 5%, (N=200) 30% 0.5% 5%, (N=200) 30% 0.5% 5%, (N=200)
Continuous, no outliers 2 1 1 2 1 1 2 4 0
Continuous with outliers 3 1 0 1 74 16 1 57 9
B i n a r y 221 161 7 082 2
This table relates to the simulation study to test the type 1 error rates of MultiPhen, CCA, and the univariate approach, described in the text. The elements of the table
show the number of results with P,1e
–5 in the scenario described by the corresponding row and column (which give the minor allele frequencies) headers. Since
100000 replicates of SNP-phenotype associations were simulated under the null hypothesis of no association, the expectation for all elements of the table is 1; those
with .1 indicating inflation of the type 1 error rate. Simulations with MAF=30%, 0.5% were performed on a sample size of N=5000. For the full results see Figures S1–
S8 and Table S1–S3.
doi:10.1371/journal.pone.0034861.t001
Joint Model of Multiple Phenotypes in GWAS
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Next we describe the application of MultiPhen to lipid traits
(total cholesterol, high and low density lipoprotein, and triglycer-
ides: CHOL, HDL, LDL and TRIG) in the Northern Finland
Birth Cohort 1966 (NFBC1966). Figures 2a and 2b illustrate the 2-
dimensional correlation structure between CHOL and LDL, and
LDL and HDL, respectively. We note from the Friedewald
Formula [17] (in units of mmol/L),
LDL&CHOL{HDL{0:45|TRIG ð1Þ
that variants with an effect on CHOL will correspond to an effect
in the direction of the X-axis in Figure 2a, as well is in the Y=X
direction in Figure 2b; whereas variants with an effect on HDL
correspond to an effect in the direction of the Y=–X direction in
Figure 2a and in the direction of the Y-axis in Figure 2b. Thus,
depending on which variables have been measured, the direction
of the effect may not be along either one of the X or Y axes and
may not be directly along any specific axis of interest. In fact we
suggest that each casual variant may have an effect in a different
direction. MultiPhen tests for variant effects on groups of
correlated phenotypes without making a prior assumption about
the direction of effect. While GWAS to date can be viewed as
having tested for effects in a single direction in the n-dimensional
space of n correlated phenotypes, we propose the use of MultiPhen
to test for effects in any direction when data on multiple correlated
phenotypes are available.
Examining the Power of MultiPhen to Detect Lipid
Associations
A study in 2010 [7] performed separate GWAS analyses on
these four lipid traits (CHOL, LDL, HDL, TRIG) in over 100,000
individuals and discovered 95 independent SNPs associated with
one or more of the traits. Here we exploit this extensive list of
established associations to assess the performance of MultiPhen,
using data from 4476 individuals in the Northern Finland Birth
Cohort 1966 (NFBC1966). We performed single phenotype
analyses and a MultiPhen analysis across the 95 SNPs (genotyped
and imputed) to test for SNP-phenotype associations with the four
lipids (see Methods). For the single phenotype analyses we selected
the minimum P value from the analyses of each of the phenotypes
for each SNP and adjusted it for multiple testing using a ‘‘Nyholt-
S ˇida ´k correction’’ [16]. Table S4 shows the phenotype correlation-
matrix for the 4 lipids.
Of the 95 known associated SNPs, 8 showed genome-wide
significance using single phenotype analyses, while a total of 11
SNPs were genome-wide significant under either MultiPhen or the
single phenotype analyses (Table 2). Furthermore, after excluding
the most associated phenotype, MultiPhen still identified 7 SNPs
as genome-wide significant, compared to only 2 significant single
phenotype associations. The difference in P values in this case was
almost uniformly in favour of MultiPhen, and for one SNP the P
value was almost 15 orders of magnitude smaller, and approxi-
mately 5 orders of magnitude smaller for another 3 SNPs. Table 3
provides the regression coefficients underlying the MultiPhen
models in the final column of Table 2. On average these linear
combinations are similar to what we would expect from the
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Figure 1. The power of MultiPhen in different scenarios of effect and correlation between phenotypes. Power results based on
simulations described in the text for MultiPhen (red lines) and the standard single-phenotype approach (black lines). Left panel: causal variant
explains 0.5% of phenotypic variance of both phenotypes. Middle panel: causal variant explains 0.5% on the phenotypic variance of the first
phenotype and 0.1% of the variance in the second phenotype. Right panel: causal variant explains 0.5% of phenotypic variance of the first phenotype
and 0% of the second phenotype.
doi:10.1371/journal.pone.0034861.g001
Figure 2. The correlation structure between pairs of lipids. The
left panel shows the correlation structure between total cholesterol
(CHOL) and low-density lipoprotein (LDL) in 5655 individuals from the
Northern Finland Birth Cohort 1966. Each circle depicts the value of
CHOL (X-axis) and LDL (Y-axis) in mmol/L for each individual. The right
panel shows the correlation structure between low-density lipoprotein
(LDL) and high-density lipoprotein (HDL), in mmol/L, in the same
individuals. The arrows in each plot show the direction of effect of a
variant affecting only CHOL or only HDL, such that the genotypes of
individuals underlying each plotted point are more likely to contain risk
alleles for the labelled lipid moving through the points in the direction
of the arrow. The diagonal arrows are based on the Friedewald Formula
(Friedewald.72). The arrows indicate that effects of variants can be in
very different directions in the 2-dimensional spaces shown; the aim of
modelling and testing linear combinations of phenotypes is to capture
effects in any direction.
doi:10.1371/journal.pone.0034861.g002
Joint Model of Multiple Phenotypes in GWAS
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correctly identifying the linear combination of phenotypes that
best approximates the most associated (unmeasured) phenotype.
This highlights the potential utility in explicitly modelling
combinations of phenotypes. MultiPhen also improves on the
level of significance of the best univariate result when applied to all
four lipids for 4 SNPs, indicating that these 4 SNPs may be
associated with other lipid traits or phenotypes not considered
here.
We also assessed the performance of MultiPhen relative to the
univariate approach over different subsets of our measured lipid
phenotypes, each reflecting hypothetical studies with measure-
ments available only on certain traits, in order to gain further
insight into the relative performance of the two approaches. We
analysed all 3-phenotype combinations of the lipids (4 analyses)
and all 2-phenotype combinations (6 analyses) and compared the
number of genome-wide significant SNPs between MultiPhen
and the univariate analyses (Figure 3 and Tables S5, S6, S7, S8,
Table 2. Results under standard GWAS and MultiPhen approaches for genome-wide significant SNPs.
SNP All 4 phenotypes 3 phenotypes after removing most associated
Best univariate MultiPhen Best univariate MultiPhen
Trait -log10 P" -log10 P Diff. Trait -log10 P1 -log10 P Diff.
rs3764261 HDL 25.6 22.2 –3.3 TRIG 1.3 16 14.7
rs4420638 LDL 12.7 8.9 –3.7 CHOL 8.7 8.2 –0.5
rs629301 LDL 12.2 10.8 –1.4 CHOL 8.2 10.7 2.5
rs964184 TRIG 10.7 8.1 –2.7 HDL 2.6 7.4 4.8
rs1367117 LDL 9.2 7.3 –1.9 CHOL 6.8 7.8 1
rs1532085 HDL 8.8 9.3 0.5 CHOL 1.6 4.4 2.8
rs6511720 LDL 8.4 5.6 –2.7 CHOL 6.2 5.4 –0.9
rs1260326 TRIG 7.8 5.4 –2.3 CHOL 1 2.5 1.5
rs1042034 LDL 6.7 9.6 2.9 TRIG 5.1 10 4.9
rs12678919 TRIG 6.2 7.8 1.5 HDL 3.9 5 1.2
rs174546 LDL 4.9 8.5 3.7 CHOL 3.3 8.9 5.6
" Nyholt-S ˇida ´k corrected for 4 comparisons. 1 Nyholt-S ˇida ´k corrected for 3 comparisons. Results compare univariate and MultiPhen P values, presented on the -log10
scale for ease of comparison, for all SNPs with genome-wide significant P values (.7.301 on the -log10 scale) from either approach. Genome-wide significant results
shown in bold. The difference in terms of orders of magnitude of the MultiPhen P value on all phenotypes is relative to the most associated univariate phenotype; and
the order of magnitude difference for MultiPhen where the most associated phenotype is excluded is relative to the univariate result also excluding the most associated
phenotype.
doi:10.1371/journal.pone.0034861.t002
Table 3. Most associated linear combinations of phenotypes at genome-wide significant SNPs.
SNP Most associated trait Maximally associated linear combination after removing most associated trait
CHOL LDL HDL TRIG
rs3764261 HDL 1 20.97 – 20.37
rs4420638 LDL 1 – 21.59 20.75
rs629301 LDL 1 – 21.07 20.74
rs964184 TRIG 1 20.87 21.18 –
rs1367117 LDL 1 – 21.38 20.71
rs1532085 HDL 1 20.91 – 20.11
rs6511720 LDL 1 – 20.78 20.31
rs1260326 TRIG 1 20.94 21.14 –
rs1042034 LDL 1 – 23.3 0.47
rs12678919 TRIG 1 21.19 21.93 –
rs174546 LDL 1 – 20.51 21.45
Average (Median) 1 20.94 21.18 20.54
Friedewald expected 1 21 21 20.45
*indicates that the SNP did not have a univariate genome-wide significant P value. Each row indicates the linear combination of phenotypes (given by the
corresponding regression coefficients) which is most associated with the given SNP under the MultiPhen regression, after removing the most associated phenotype.
The regression coefficients have been scaled so that the CHOL coefficient is always equal to one. The last row contains the expected coefficients according to the
Friedewald Formula (Equation 1).
doi:10.1371/journal.pone.0034861.t003
Joint Model of Multiple Phenotypes in GWAS
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in total, MultiPhen produced a larger number of genome-wide
significant SNPs than the univariate approach in 8 analyses and
the same number in 3. While in some examples, the single
phenotype analysis generates P values 2–3 orders of magnitude
smaller than MultiPhen, no univariate SNP-phenotype associa-
tion P values are 4 orders of magnitude or more smaller than the
corresponding MultiPhen result. In contrast, there are 10
MultiPhen P values smaller than the univariate P values by at
least 4 orders. MultiPhen identifies 21% more SNP-phenotype
associations than the univariate approach, with 75 compared to
62 significant associations, relating to 12 SNPs. By combining all
significant univariate and MultiPhen SNPs there are a total of 85
SNP-phenotype associations with P,2.5x10
–8 (conservative
Bonferonni correction applied), compared to 62 using the
univariate strategy only. Therefore, based on these empirical
findings, MultiPhen provides a 21% increase in detection of
susceptibility loci if used instead of the single phenotype
approach, and a 37% increase in detection if used in addition
to univariate analyses.
In order to test for false-positive results and assess any
inflation of the test statistic, we applied MultiPhen to the four
lipids genome-wide. The only genome-wide significant findings
were from loci harbouring one of the established 95 lipid SNPs,
confirming no false-positive results in these analyses. The
inflation factor of the test statistic calculated from the
genome-wide MultiPhen results was 1.06, indicating no unusual
inflation of the test statistic. While we did not detect novel
susceptibility loci using MultiPhen in the NFBC1966, this was
not unexpected given that the sample size of Teslovich et al. [7]
that reported the 95 SNPs was ,21 times greater than the
present study.
Discussion
Since the emergence of GWAS in 2007 with two seminal
publications [1], [18], the approach of testing the association
between a genetic variant and phenotype, each one-at-time, has
remained the method of choice. However, despite the develop-
ment of multivariate methods, so far there has been limited
application to GWAS datasets. In this report, we have shown
with both real and extensively simulated data the extent of the
power gains that can be achieved through the multivariate
approach.
We have introduced a new multivariate method, MultiPhen,
which addresses limitations of alternative multivariate methods.
Key advantages of our approach are its computational speed, the
modelling and subsequent availability of the linear combination of
phenotypes most associated with each genotype, and its applica-
tion to both quantitative – regardless of phenotype distribution –
and case-control data.
We demonstrated that the MultiPhen model provides appro-
priate type 1 error rate when applied to both common and rare
variants, non-normal continuous phenotypes and binary pheno-
types. In contrast, CCA [15] and the univariate approach used
here have inflated type 1 error rates when applied to non-normal
continuous phenotypes or binary phenotypes at low frequency
variants. We also demonstrated via application to simulated and
real data that MultiPhen can achieve substantial increases in
statistical power to detect true associations. Simulations show that
Figure 3. Genome-wide significant results from standard GWAS approach and MultiPhen tested on combinations of the lipids
using NFBC1966 data. Each bar shows the number of SNPs reaching genome-wide significance for a given phenotype-combination analysis
(specified by the first letters of each trait, such that CHL refers to an analysis on the CHOL, HDL and LDL), with the SNPs discovered by both the
univariate approach and MultiPhen shown by the white segment of the bar, the SNPs discovered by the univariate approach only shown by the grey
segment, and the SNPs discovered by MultiPhen only illustrated by the black segment. The bars labelled ALL2 and ALL3 combine results across
analyses on all combinations of two and three lipid traits, respectively, while ALL combines the results across the analyses of all 2, 3 and 4
combinations of the traits. A complete breakdown of these results is presented in Tables S5, S6, S7, S8, S9, S10, S11, S12, S13, S14, S15.
doi:10.1371/journal.pone.0034861.g003
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phenotypes and the genetic effects on them, and can be marginally
greater for the univariate approach, most of the model space
corresponds to significantly higher power for MultiPhen. We find
that CCA and MultiPhen have almost the same statistical power
when applied to normally distributed phenotypes. The dramatic
gains in power for MultiPhen over the univariate approach when
the genetic effects and phenotypic correlations are discordant,
suggest that MultiPhen may discover causal variants not amenable
to discovery by the univariate approach even with large increases
in sample size. The application of MultiPhen to lipid traits in the
NFBC1966 provides supportive evidence for the performance of
MultiPhen using real data.
By considering all 2, 3, and 4 phenotype combinations of the 4
lipid traits we were able to test empirically the performance of
MultiPhen applied to phenotypes with different correlation
structures, in comparison with the univariate approach. These
results indicate a 21% greater yield of SNP-phenotype associations
when MultiPhen is applied instead of the univariate approach, and
a 37% increased yield over the univariate analysis when significant
univariate and MultiPhen results are combined. However, given
that these analyses relate to a limited number of phenotypes and
significant SNPs, these figures should not be considered accurate
estimates of the general performance of MultiPhen over the
univariate approach, which can only be obtained from extensive
future use on a variety of phenotypes. Our findings on the lipid
data are, however, supportive of the results from our simulation
study in indicating that MultiPhen may lead to greater discovery
when used instead of the univariate approach, and suggest that
applying both approaches and combining results could lead to
even greater discovery.
We consider it likely that causal variants commonly influence
many separately defined phenotypes [19], with protein products
acting as intermediaries in complex causal networks. We suggest
that this most likely applies to correlated phenotypes since these
must share risk factors and most likely have common biological
pathways. We propose that the association between genotype
and an unmeasured protein product, or other unmeasured
mediator or uncharacterised phenotype, may be captured by a
linear combination of measured phenotypes that are affected.
Moreover, we have shown that we can recapitulate the
Friedewald Formula (Equation 1) for the 4 lipid traits studied
here using the average regression coefficient over multiple SNPs.
This strategy may help to refine the definition of existing
phenotypes and also suggest novel phenotypes for further
investigation, thus providing insights into underlying biological
processes and diseases.
An overlap in loci identified by GWAS on different phenotypes
[20], as well as greater availability of data on multiple phenotypes
in GWAS consortia, has led to increased interest in studying
multiple phenotypes together in GWAS [21]. Here we have
introduced a simple and computationally fast method and software
for performing GWAS on multiple phenotypes jointly, suitable for
application to directly genotyped or imputed SNP or CNV data
for association testing with quantitative or case-control pheno-
types. MultiPhen should be considered a discovery tool for
application to multiple correlated phenotypes that makes no prior
assumptions about the nature of the genetic effects on the
phenotypes. Over a wide range of plausible scenarios, MultiPhen
can achieve marked increases in power, both when the genetic
variant affects more than one phenotype and when it affects only a
single phenotype (Figure 1). We propose the use of MultiPhen in
future GWAS on multiple correlated phenotypes as a rapid, user-
friendly and effective means to reveal novel susceptibility loci that
would have been missed by the standard single-phenotype
approach.
Materials and Methods
Ethics Statement
This study was approved by the Ethical Committee of the
Northern Ostrobothnia Hospital District; written, informed
consent was obtained from all participants.
MultiPhen Approach
In the standard GWAS approach, when considering a
quantitative phenotype, a linear regression is usually performed
of phenotype, Y, on genotype, X. We let Yi={Yi1,… ,YiK} denote
the phenotype data corresponding to K phenotypes for an
individual i and Xi={Xi1,… ,XiG} denote their genotype data at
G SNPs, where Xig e {0,1,2}. The regression performed at a SNP,
g, and a phenotype, k, to test for association between the SNP
genotypes and the phenotype is thus:
Yik~akzbgkXigzeigk
where eigk is the residual error assumed to be normally distributed.
The null hypothesis of no association between SNP and genotype
can be tested by performing a t-test on the null hypothesis bgk~0.
In our MultiPhen approach we invert the regression so that the
SNP genotypes, X, become the dependent variable, and the K
phenotypes under study become the predictor variables. The
genotype data is an allele count and is therefore modelled using
ordinal regression; we use proportional odds logistic regression.
This model defines the class probabilities as follows.
P(Xigƒm)~
1
1ze
({agm{
P K
k~1
bgkYik)
At each SNP g=1,…,G we use a likelihood ratio test to test the
null hypothesis bg1=…=bgK=0. This test does not assume
Hardy-Weinberg Equilibrium.
Application to Lipid Trait Data in the NFBC1966
Complete genotype and lipid trait data were available on 4476
individuals (5655 individuals with complete lipid data, used in
Figure 2) from the Northern Finland Birth Cohort 1966
(NFBC1966) across the 95 lipid SNPs established in Teshlovich
et al. [7]. In the NFBC1966, mothers living in the two northern-
most provinces of Finland were invited to participate if they had
expected delivery dates during 1966. At age 31, 5,923 individuals
from the cohort still living in the Helsinki area or Northern
Finland were asked to participate in a detailed biological and
medical examination, from which the genotype and lipid data
derive. Genotypes that were not directly measured were imputed
using IMPUTE [22]. Single phenotype analyses were performed
using linear regression in the MultiPhen package (see below), and
the P values obtained from each analysis at each SNP were
subsequently corrected for multiple testing using a ‘‘Nyholt- S ˇida ´k
correction’’ [16] based on the correlation matrix of the lipids
(Table S4); where the number of effective tests is calculated using
the approach taken in Nyholt 2004 [16] and then used to compute
aS ˇida ´k corrected P value [23].
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We tested the MultiPhen model using simulated genotype
and phenotype data. Genotype data was simulated for 5000
individuals assuming a minor allele frequency of 20% and
Hardy-Weinberg Equilibrium. For each individual two contin-
uous phenotypes were simulated given the genotype data,
controlling the heritability of each phenotype and the correla-
tion between phenotypes. The two phenotypes were simulated
from the following models:
Yi1~bG1XizbE1Ei
Yi2~bG2XizbE2Eize
where Xi is the simulated genotype data taking values 0, 1 and
2, Ei , N(0,1) represents a common environmental effect
affecting both phenotypes, and e is a random effect distributed
N(0,s
2). Heritability is defined as the proportion of the variance
of the trait due to genetic heterogeneity. According to the above
models the variances of the two traits are given by:
V(Y1)~2p(1{p)b
2
G1zb
2
E1
V(Y2)~2p(1{p)b
2
G2zb
2
E2zs2
where p is the allele frequency. Therefore, if we choose parameters
such thatV(Y1)~V(Y2)~1, then the heritability of trait k is
hk~2p(1{p)b
2
Gk.
If the traits are centered to both have mean 0, then the
correlation between the traits is:
cor(Y1,Y2)~2p(1{p)bG1bG2zbE1bE2 ð2Þ
To simulate all scenarios in the simulation study we solve for
bE1,bE2 and s
2 conditional on V(Y1)~V(Y2)~1 and the desired
correlation (2).
MultiPhen has its worst power when the association of Y2 with X
is explained by Y1 (or vice versa). That is to say, when the residuals
of Y2, regressing out the effect of Y1, are independent of X.I fY
0
i2
are the residuals of Y2 regressed on Y1 for individuals i=1, …, N,
then:
Y
0
i2~Yi2{Yi1
P N
j~1
Yj1Yj2
P N
j~1
Y2
j1
ð3Þ
Regressing Y1 and Y2 on X gives:
Yi1~a1zb1Xi ð4Þ
Yi2~a2zb2Xi ð5Þ
Substituting (4) and (5) into (3) gives:
Y
0
i2~a2{a1
P N
j~1
Yj1Yj2
P N
j~1
Y2
j1
zXi(b2{b1
P N
j~1
Yj1Yj2
P N
j~1
Y2
j1
):
Therefore Y
0
i2 is independent of Xi when b2~b1
P N
j~1
Yj1Yj2
P N
j~1
Y2
j1
:
For standardised phenotype data, Y
0
i2is independent of Xi when
b2
b1 ~cor(Y1,Y2), that is, when the ratio of the genetic effects is
equal to the correlation between the phenotypes.
Binary traits were simulated assuming a classical liability
threshold model. We used the same simulation as for continuous
traits assuming the continuous traits were liability phenotypes. In
this model all individuals with liability phenotypes greater than a
threshold t were assumed to be a case for that trait. Heritability on
the observed scale is given by:
h2
o~
h2
l z2
q(1{q)
Where q is the disease prevalence and z is the height of the
normal pdf at the threshold value t. All correlations on Figures
relating to simulations involving binary traits (Figures S11 and
S12) are with respect to liabilities. Case-control data was simulated
by randomly sampling cases and controls from a large simulated
population.
MultiPhen Software
The MultiPhen software was written in the R statistical
language. R users can download and install MultiPhen from
CRAN (http://cran.r-project.org/) or any CRAN mirror, with
documentation available here:
http://cran.r-project.org/web/packages/MultiPhen/
MultiPhen.pdf. Alternatively, a Java executable can be download-
ed from http://www1.imperial.ac.uk/medicine/people/l.coin/.
Supporting Information
Figure S1 Behaviour under the null: without outliers,
MAF=30%. QQ-plots, corresponding to MultiPhen, CCA and
the univariate approach (Nyolt-S ˇida ´k corrected) applied to data
simulated under the null hypothesis of no SNP-phenotype effects
(100000 replicates for each), sample size N=5000, with MAF of
simulated SNPs of 30% and 2 normally distributed phenotypes
(without outliers) and correlations between the phenotypes of 0,
0.5 and 0.9. The plots show that all three methods have an
appropriate null distribution, even when the correlation between
the phenotypes is high.
(TIFF)
Figure S2 Behaviour under the null: without outliers,
MAF=0.5%. QQ-plots, corresponding to MultiPhen, CCA and
the univariate approach (Nyolt-S ˇida ´k corrected) applied to data
simulated under the null hypothesis of no SNP-phenotype effects
(100000 replicates for each), sample size N=5000, with MAF of
simulated SNPs of 0.5% and 2 normally distributed phenotypes
(without outliers) and correlations between the phenotypes of 0,
0.5 and 0.9. The plots show that all three methods have an
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the phenotypes is high.
(TIFF)
Figure S3 Behaviour under the null: with outliers,
MAF=30%. QQ-plots, corresponding to MultiPhen, CCA and
the univariate approach (Nyolt-S ˇida ´k corrected) applied to data
simulated under the null hypothesis of no SNP-phenotype effects
(100000 replicates for each), sample size N=5000, with MAF of
simulated SNPs of 30% and 2 phenotypes where one has an
outlier distribution and correlations between the phenotypes of 0,
0.5 and 0.9. The plots show that all three methods have an
appropriate null distribution, even when the correlation between
the phenotypes is high.
(TIFF)
Figure S4 Behaviour under the null: with outliers,
MAF=0.5%. QQ-plots, corresponding to MultiPhen, CCA
and the univariate approach (Nyolt-S ˇida ´k corrected) applied to
data simulated under the null hypothesis of no SNP-phenotype
effects (100000 replicates for each), sample size N=5000, with
MAF of simulated SNPs of 0.5% and 2 phenotypes where one has
an outlier distribution and correlations between the phenotypes of
0, 0.5 and 0.9. The plots show that while MultiPhen has an
appropriate null distribution, even when the correlation between
the phenotypes is high, the other two approaches have a highly
inflated null distribution, which would produce an extremely high
type 1 error rate, irrespective of the correlation between the
phenotypes.
(TIFF)
Figure S5 Behaviour under the null: with outliers,
MAF=5% (N=200). QQ-plots, corresponding to MultiPhen,
CCA and the univariate approach (Nyolt-S ˇida ´k corrected) applied
to data simulated under the null hypothesis of no SNP-phenotype
effects (100000 replicates for each), sample size N=200, with
MAF of simulated SNPs of 5% and 2 phenotypes where one has
an outlier distribution and correlations between the phenotypes of
0, 0.5 and 0.9. The plots show that while MultiPhen has an
appropriate null distribution, even when the correlation between
the phenotypes is high, the other two approaches have an inflated
null distribution. Thus CCA and the univariate approach can have
a high type 1 error rate for common, as well as rare, variants.
(TIFF)
Figure S6 Behaviour under the null: binary phenotypes,
MAF=30%. QQ-plots, corresponding to MultiPhen, CCA and
the univariate approach (Nyolt-S ˇida ´k corrected) applied to case-
control study data simulated under the null hypothesis of no SNP-
phenotype effects (100000 replicates for each), with sample size
N=5000 such that the first phenotype has 50% cases and controls
whereas the second phenotype has 10% cases and 90% controls
(case-control status defined according to the simulated values of
underlying normally distributed continuous phenotypes). The
MAF of the simulated SNPs is 30% and the correlations between
the phenotypes (on a liability scale) are 0, 0.5 and 0.9. The plots
show that all three methods have an appropriate null distribution
when there are no SNP-phenotype effects, even when correlation
between the phenotypes is high.
(TIFF)
Figure S7 Behaviour under the null: binary phenotypes,
MAF=0.5%. QQ-plots, corresponding to MultiPhen, CCA and
the univariate approach (Nyolt-S ˇida ´k corrected) applied to case-
control study data simulated under the null hypothesis of no SNP-
phenotype effects (100000 replicates for each), with sample size
N=5000 such that the first phenotype has 50% cases and controls
whereas the second phenotype has 10% cases and 90% controls
(case-control status defined according to the simulated values of
underlying normally distributed continuous phenotypes). The
MAF of the simulated SNPs is 0.5% and the correlations between
the phenotypes (on a liability scale) are 0, 0.5 and 0.9. The plots
show that while MultiPhen has an appropriate null distribution,
even when the correlation between the phenotypes is high, the
other two approaches have an inflated null distribution.
(TIFF)
Figure S8 Behaviour under the null: binary phenotypes,
MAF=5% (N=200). QQ-plots, corresponding to MultiPhen,
CCA and the univariate approach (Nyolt-S ˇida ´k corrected) applied
to case-control study data simulated under the null hypothesis of
no SNP-phenotype effects (100000 replicates for each), with
sample size N=200 such that the first phenotype has 50% cases
and controls whereas the second phenotype has 10% cases and
90% controls (case-control status defined according to the
simulated values of underlying normally distributed continuous
phenotypes). The MAF of the simulated SNPs is 5% and the
correlations between the phenotypes (on a liability scale) are 0, 0.5
and 0.9. The plots show that while MultiPhen has an appropriate
null distribution, even when the correlation between the
phenotypes is high, the other two approaches have an inflated
null distribution.
(TIFF)
Figure S9 The power of MultiPhen in scenarios where
the effect on the phenotypes is in the opposite direction.
Power results based on simulations described in the text for
MultiPhen (red lines) and the standard single-phenotype approach
(black lines). Left panel: causal variant explains 0.5% of
phenotypic variance of both phenotypes but in opposite directions.
Right panel: causal variant explains 0.5% of the phenotypic
variance of the first phenotype and 0.1% of the variance in the
second phenotype in the opposite direction of the effect on the
first. The X-axis corresponds to the correlation (Pearson’s
correlation coefficient, r) between the phenotypes.
(TIFF)
Figure S10 The power of MultiPhen applied to two,
three, five and ten phenotypes. Power results based on
simulations described in the text for MultiPhen (red lines) and the
standard single-phenotype approach (black lines), for 2 (bold), 3
(dashed), 5 (dotted), and 10 (dashed/dotted) phenotypes. Left
panel: causal variant explains 0.5% of phenotypic variance of each
phenotype. Middle panel: causal variant explains 0.5% of the
phenotypic variance of the first phenotype and 0.1% of the
variance in each of the other phenotypes. Right panel: causal
variant explains 0.5% of phenotypic variance of the first
phenotype and 0% of each of the other phenotypes. The X-axis
corresponds to the correlation (Pearson’s correlation coefficient, r)
between all pairs of phenotypes (that is, the correlation between
each pair of phenotypes is the same at each point of the X-axis).
The results are truncated when the pairwise correlations are low
for multiple phenotypes because the corresponding correlation
matrices of the phenotypes are not positive definite and so the
multivariate gaussian distributions cannot be sampled via the
Cholesky decomposition that we perform.
(TIFF)
Figure S11 The power of MultiPhen applied to two case-
control phenotypes. Power results based on simulations
described in the text for MultiPhen (red lines) and the standard
single-phenotype approach (black lines) applied to two indepen-
dent case-control studies, each with 1000 cases and 1000 controls
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Heritability on the liability scale is 0.1% for one phenotype and
0.1% (left panel), 0.05% (middle panel) and 0% (right panel) for
the other phenotype. Solid and dashed are for disease prevalences
of 1% and 0.5%, respectively, for both studies. Correlation on the
X-axis is with respect to the liability scale.
(TIFF)
Figure S12 The power of MultiPhen applied to one case-
control and one quantitative phenotype. The power of
MultiPhen applied to a case-control study with 1000 cases and 1000
controls using case-controlstatus and a single measured quantitative
phenotype as predictor variables. Heritability of the continuous
phenotype is 0.2%; heritability of the binary trait on the liability
scale is: 0.5% (a), 0.1% (b) and 0% (c). Solid and dashed lines are for
disease prevalence of 1% and 0.5% respectively. Correlation on the
X-axis is with respect to the liability scale.
(TIFF)
Figure S13 The power of CCA, compared to MultiPhen
and the univariate approach. Power results based on
simulations described in the text for CCA (blue), MultiPhen (red)
and the single-phenotype approach (black), when applied to two
continuous normally distributed phenotypes where the causal
variant explains 0.5% of the phenotypic variance of the first
phenotype and 0.1% of the variance of the other phenotype, with
the simulatedSNPs having MAF=30%. The X-axis corresponds to
the correlation (Pearson’s correlation coefficient, r) between the
phenotypes. The difference in statistical power between CCA and
MultiPhen in this scenario is reflective of the difference in power
when the effect of the causal variants on the phenotypes differs and
for different allele frequencies of the causal variant (data not shown).
(TIFF)
Table S1 Behaviour under the null: r=0. The table relates
to thesimulation studyto test the behaviourofthe differentmethods
under the null hypothesis of no association, describedinthetext and
presented inFigures S1–S8.Theelementsof the table correspond to
the number of results with P values smaller than that of the
corresponding column header (expected number given in the
second row of the column header), with the simulation scenario
given in the left-hand column. This table gives the results for all
simulations where the two phenotypes have a correlation of r=0.
(PDF)
Table S2 Behaviour under the null: r=0.5. The table
relates to the simulation study to test the behaviour of the different
methods under the null hypothesis of no association, described in
the text and presented in Figures S1–S8. The elements of the table
correspond to the number of results with P values smaller than that
of the corresponding column header (expected number given in the
second row of the column header), with the simulation scenario
given in the left-hand column. This table gives the results for all
simulations where the two phenotypes have a correlation of r=0.5.
(PDF)
Table S3 Behaviour under the null: r=0.9. The table
relates to the simulation study to test the behaviour of the different
methods under the null hypothesis of no association, described in
the text and presented in Figures S1–S8. The elements of the table
correspond to the number of results with P values smaller than that
of the corresponding column header (expected number given in
the second row of the column header), with the simulation
scenario given in the left-hand column. This table gives the results
for all simulations where the two phenotypes have a correlation of
r=0.9.
(PDF)
Table S4 Correlation matrix for the 4 lipids (CHOL,
TRIG, HDL, LDL) based on the NFBC1966 data. The
upper triangular elements of the correlation matrix show the
pairwise Pearson’s correlation coefficient (r) between each pair of
the traits: total cholesterol (CHOL), triglycerides (TRIG), high-
density lipoprotein (HDL) and low-density lipoprotein (LDL).
(PDF)
Table S5 Results under standard GWAS and MultiPhen
approaches for genome-wide significant SNPs: CHOL-
TRIG-HDL-LDL combination. Results compare univariate
and MultiPhen P values, presented on the -log10 scale for ease of
comparison, for all SNPs with genome-wide significant P values
(.7.301 on the -log10 scale) from either approach. Genome-wide
significant results shown in bold (only the smallest univariate result
highlighted since this corresponds to the P value for the group of
single phenotype analyses. Note, all univariate results are Nyholt-
S ˇida ´k corrected). The difference in terms of orders of magnitude of
the MultiPhen P value and the smallest univariate P value for each
SNP is given in the final column.
(PDF)
Table S6 Results under standard GWAS and MultiPhen
approaches for genome-wide significant SNPs: TRIG-
HDL-LDL combination. Results compare univariate and
MultiPhen P values, presented on the -log10 scale for ease of
comparison, for all SNPs with genome-wide significant P values
(.7.301 on the -log10 scale) from either approach. Genome-wide
significant results shown in bold (only the smallest univariate result
highlighted since this corresponds to the P value for the group of
single phenotype analyses. Note, all univariate results are Nyholt-
S ˇida ´k corrected). The difference in terms of orders of magnitude of
the MultiPhen P value and the smallest univariate P value for each
SNP is given in the final column.
(PDF)
Table S7 Results under standard GWAS and MultiPhen
approaches for genome-wide significant SNPs: CHOL-
HDL-LDL combination. Results compare univariate and
MultiPhen P values, presented on the -log10 scale for ease of
comparison, for all SNPs with genome-wide significant P values
(.7.301 on the -log10 scale) from either approach. Genome-wide
significant results shown in bold (only the smallest univariate result
highlighted since this corresponds to the P value for the group of
single phenotype analyses. Note, all univariate results are Nyholt-
S ˇida ´k corrected). The difference in terms of orders of magnitude of
the MultiPhen P value and the smallest univariate P value for each
SNP is given in the final column.
(PDF)
Table S8 Results under standard GWAS and MultiPhen
approaches for genome-wide significant SNPs: CHOL-
TRIG-LDL combination. Results compare univariate and
MultiPhen P values, presented on the -log10 scale for ease of
comparison, for all SNPs with genome-wide significant P values
(.7.301 on the -log10 scale) from either approach. Genome-wide
significant results shown in bold (only the smallest univariate result
highlighted since this corresponds to the P value for the group of
single phenotype analyses. Note, all univariate results are Nyholt-
S ˇida ´k corrected). The difference in terms of orders of magnitude of
the MultiPhen P value and the smallest univariate P value for each
SNP is given in the final column.
(PDF)
Table S9 Results under standard GWAS and MultiPhen
approaches for genome-wide significant SNPs: CHOL-
TRIG-HDL combination. Results compare univariate and
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comparison, for all SNPs with genome-wide significant P values
(.7.301 on the -log10 scale) from either approach. Genome-wide
significant results shown in bold (only the smallest univariate result
highlighted since this corresponds to the P value for the group of
single phenotype analyses. Note, all univariate results are Nyholt-
S ˇida ´k corrected). The difference in terms of orders of magnitude of
the MultiPhen P value and the smallest univariate P value for each
SNP is given in the final column.
(PDF)
Table S10 Results under standard GWAS and Multi-
Phen approaches for genome-wide significant SNPs:
CHOL-TRIG combination. Results compare univariate and
MultiPhen P values, presented on the -log10 scale for ease of
comparison, for all SNPs with genome-wide significant P values
(.7.301 on the -log10 scale) from either approach. Genome-wide
significant results shown in bold (only the smallest univariate result
highlighted since this corresponds to the P value for the group of
single phenotype analyses. Note, all univariate results are Nyholt-
S ˇida ´k corrected). The difference in terms of orders of magnitude of
the MultiPhen P value and the smallest univariate P value for each
SNP is given in the final column.
(PDF)
Table S11 Results under standard GWAS and Multi-
Phen approaches for genome-wide significant SNPs:
CHOL-HDL combination. Results compare univariate and
MultiPhen P values, presented on the -log10 scale for ease of
comparison, for all SNPs with genome-wide significant P values
(.7.301 on the -log10 scale) from either approach. Genome-wide
significant results shown in bold (only the smallest univariate result
highlighted since this corresponds to the P value for the group of
single phenotype analyses. Note, all univariate results are Nyholt-
S ˇida ´k corrected). The difference in terms of orders of magnitude of
the MultiPhen P value and the smallest univariate P value for each
SNP is given in the final column.
(PDF)
Table S12 Results under standard GWAS and Multi-
Phen approaches for genome-wide significant SNPs:
CHOL-LDL combination. Results compare univariate and
MultiPhen P values, presented on the -log10 scale for ease of
comparison, for all SNPs with genome-wide significant P values
(.7.301 on the -log10 scale) from either approach. Genome-wide
significant results shown in bold (only the smallest univariate result
highlighted since this corresponds to the P value for the group of
single phenotype analyses. Note, all univariate results are Nyholt-
S ˇida ´k corrected). The difference in terms of orders of magnitude of
the MultiPhen P value and the smallest univariate P value for each
SNP is given in the final column.
(PDF)
Table S13 Results under standard GWAS and Multi-
Phen approaches for genome-wide significant SNPs:
TRIG-HDL combination. Results compare univariate and
MultiPhen P values, presented on the -log10 scale for ease of
comparison, for all SNPs with genome-wide significant P values
(.7.301 on the -log10 scale) from either approach. Genome-wide
significant results shown in bold (only the smallest univariate result
highlighted since this corresponds to the P value for the group of
single phenotype analyses. Note, all univariate results are Nyholt-
S ˇida ´k corrected). The difference in terms of orders of magnitude of
the MultiPhen P value and the smallest univariate P value for each
SNP is given in the final column.
(PDF)
Table S14 Results under standard GWAS and Multi-
Phen approaches for genome-wide significant SNPs:
TRIG-LDL combination. Results compare univariate and
MultiPhen P values, presented on the -log10 scale for ease of
comparison, for all SNPs with genome-wide significant P values
(.7.301 on the -log10 scale) from either approach. Genome-wide
significant results shown in bold (only the smallest univariate result
highlighted since this corresponds to the P value for the group of
single phenotype analyses. Note, all univariate results are Nyholt-
S ˇida ´k corrected). The difference in terms of orders of magnitude of
the MultiPhen P value and the smallest univariate P value for each
SNP is given in the final column.
(PDF)
Table S15 Results under standard GWAS and Multi-
Phen approaches for genome-wide significant SNPs:
HDL-LDL combination. Results compare univariate and
MultiPhen P values, presented on the -log10 scale for ease of
comparison, for all SNPs with genome-wide significant P values
(.7.301 on the -log10 scale) from either approach. Genome-wide
significant results shown in bold (only the smallest univariate result
highlighted since this corresponds to the P value for the group of
single phenotype analyses. Note, all univariate results are Nyholt-
S ˇida ´k corrected). The difference in terms of orders of magnitude of
the MultiPhen P value and the smallest univariate P value for each
SNP is given in the final column.
(PDF)
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